The Board shall advise the Directors of CCR and DCEG, and the Director and Deputy Directors, NCI, on a wide variety of matters concerning scientific program policy and progress and future direction of research programs in the areas of carcinogenesis; cancer biology and diagnosis; cancer center administration; medicine; radiological and surgical oncology; chemotherapy; cancer epidemiology, genetics, genomics, and related areas; cancer education; cancer information services; community outreach; biological, chemical and physical carcinogenesis; DNA repair; tumor biology and immunology; humoral and cellular immunity; hematopoiesis; cell differentiation and transformation; oncogenes and growth factors; molecular and structural biology; genetic regulation; cell signaling; viral oncology; vaccine development; transplantation; clinical trial design, management and evaluation; pharmacology; drug development and developmental therapeutics; proteomics; genetic and immunotherapies; pathology; diagnostic research and cytogenetics; biological response modifiers; imaging; nutrition; survey research; epidemiology; biostatistics; statistics; rehabilitation; psychology and behavioral medicine; public health and community oncology; quality of life; pain management; cancer detection and diagnosis; cancer treatment and restorative care; dentistry; nursing; public health; education of health professionals; medical oncology; surgery; radiotherapy; gynecologic oncology; and pediatric oncology.